Williams M R, Todd J H, Ellis I O, Dowle C S, Haybittle J L, Elston C W, Nicholson R I, Griffiths K, Blamey R W
Br J Cancer. 1987 Jan;55(1):67-73. doi: 10.1038/bjc.1987.14.
ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%.
对704例可手术乳腺癌患者的原发肿瘤组织进行了雌激素受体（ER）含量检测。目前中位随访时间为84个月，且无一例患者接受过任何形式的辅助治疗。ER状态与组织学分级、绝经状态、转移初始部位及后续内分泌治疗反应相关。在ER阳性患者中发现了生存方面的显著优势，这仅限于乳房切除时淋巴结阳性的患者。在淋巴结阳性患者中，无病生存期（DFI）也与ER状态显著相关。ER阳性肿瘤患者出现转移症状并开始内分泌治疗后的生存期延长。在可评估的ER阳性肿瘤患者中，内分泌治疗的总体缓解率为32%。通过结合肿瘤组织的ER状态和组织学分级，可以识别出一组占可接受内分泌治疗患者28%的患者（ER阳性，I级和II级），其缓解率为46%。
